AZOM on MSN9h
esmo group Launches Apollo Quad Handler to Revolutionize Semiconductor Testing
esmo group (esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation solutions, is proud to announce the launch of its latest product—the ...
Medical Xpress21h
Largest T cell clinical trial in solid tumors explores potential for precision immunotherapy
A comprehensive analysis of the Phase II EBV CTL trial conducted at NCCS that identifies biomarkers will be presented at the ...
Business Insider14h
BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin
There were no treatment-related deaths. Results are consistent with the data reported on the first 19 patients in Study 303 at ESMO in September. Published first on TheFly – the ultimate source for ...
Renal & Urology News21h
Will Durvalumab Transform Standard Care in MIBC?
in patients with muscle-invasive bladder cancer (MIBC), according to findings from the phase 3 NIAGARA study presented at the ...
Business Insider14h
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...
EurekAlert!15h
Largest T cell clinical trial in solid tumors heralds new era in precision immunotherapy
The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III ...
Armed robbery in Revesby15h
Major T Cell Trial in Solid Tumors Marks New Era
The largest ever clinical trial of T cell therapy for solid tumours has ended, heralding a new era for precision T cell ...
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...
The Pharma Letter5d
16th European Multidisciplinary Congress on Urological Cancers
The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...
pharmaphorum2d
ESMO: Incyte's PD-1 treads new ground in anal cancer
Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...